Newsfeeds Archive - Spark Newswire

1 minute read

GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024

May 29, 4:03 PM

GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion

GLYC

2 minute read

Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge

By Avi Kapoor

May 6, 3:04 PM

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100…

EYPT

2 minute read

Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results

By Avi Kapoor

May 6, 12:48 PM

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.…

EYPT

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

May 6, 12:31 PM

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday’s regular session. The company’s market cap…

AFIB

2 minute read

Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views

By Avi Kapoor

May 6, 11:14 AM

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday. The…

EYPT

2 minute read

GlycoMimetics’ Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink

By Vandana Singh

May 6, 9:13 AM

Get insights on GlycoMimetics Inc's Phase 3 study results for uproleselan in R/R AML patients. Explore survival rates, adverse events, and future analyses.

GLYC